Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel molecule product candidates for immuno-inflammatory diseases. Its pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trials for conditions such as moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease. The company also has ATI-2138, a dual inhibitor of ITK and JAK3 in Phase 2a for T cell-mediated autoimmune diseases, and ATI-052, a bispecific antibody in Phase 1b targeting various atopic and respiratory diseases. Additionally, Aclaris is developing ATI-9494, an oral dual inhibitor of ITK and TXK, and Lepzacitinib, a soft JAK 1/3 inhibitor for dermatologic conditions.

Aclaris Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ACRS. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company is headquartered in Wayne, Pennsylvania, and operates within the US market.

Aclaris Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel therapies for immuno-inflammatory diseases, which falls under the broader biotechnology umbrella. The company's work involves monoclonal antibodies, bispecific antibodies, and small molecule inhibitors targeting immune pathways.

Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, United States. The company primarily serves the US market, as indicated by its country designation and regional classification. Its clinical trials and product development are focused on addressing immuno-inflammatory diseases prevalent in the US population, though the company's pipeline targets conditions that affect patients globally.

Aclaris Therapeutics has a diverse pipeline of product candidates for immuno-inflammatory diseases. Bosakitug (ATI-045) is an anti-TSLP monoclonal antibody in Phase 2 trials for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and COPD. ATI-2138 is a dual ITK/JAK3 inhibitor in Phase 2a for T cell-mediated autoimmune diseases. ATI-052 is a bispecific antibody targeting TSLP and IL4R in Phase 1b for atopic and respiratory diseases. ATI-9494 is an oral dual ITK/TXK inhibitor, and Lepzacitinib is a soft JAK 1/3 inhibitor for dermatologic conditions. These candidates represent the company's focus on novel mechanisms to modulate immune responses.